Harmony Biosciences (HRMY) Q4 2025 earnings review
WAKIX Nears Blockbuster Status, But Q4 Margins Take a Sudden Hit
Harmony Biosciences closed 2025 with strong top-line momentum, as WAKIX net revenue grew 21% YoY to $243.8M in Q4, driven by a consistent addition of ~400 patients. The company initiated FY26 revenue guidance of $1.0-$1.04 billion, paving the way for WAKIX to achieve blockbuster status. However, the bottom line tells a reversing story: GAAP net income plunged 55% YoY to $22.5M, and Adjusted Net Income nearly halved to $33.4M. This profit compression was driven by a sudden 50% YoY surge in operating expenses, anchored by a 99% spike in G&A. While Harmony's balance sheet remains robust with $882.5M in cash to self-fund its pipeline, the abrupt degradation in earnings quality contradicts the management's 'profitable biotech' narrative and warrants investor scrutiny.
🐂 Bull Case
The core narcolepsy franchise added ~400 patients in Q4, reaching ~8,500 total. The consistent commercial execution virtually guarantees surpassing $1B in FY26 sales.
With the Pitolisant GR NDA on track for Q2 2026 and Phase 3 trials initiated for Pitolisant HD, Harmony is successfully executing its strategy to extend the franchise's lifecycle into the 2040s.
🐻 Bear Case
Total Operating Expenses surged 50% YoY in Q4, dramatically outpacing 21% revenue growth. A 99% spike in G&A severely compressed margins and cut Adjusted Net Income by almost half.
Despite settlements pushing generic entry to March 2030, the reliance on a single commercial product creates intense pressure on the clinical pipeline to deliver approved, revenue-generating assets before the WAKIX patent cliff.
⚖️ Verdict: ⚪
Neutral. Top-line execution is flawless and the WAKIX growth engine remains stable. However, the severe margin compression in Q4 introduces significant earnings quality concerns, forcing investors to weigh robust revenue generation against rapidly escalating operational costs.
Key Themes
Q4 Operating Expense Shock Crushes Profitability
A major red flag emerged in Q4 profitability. Despite generating $42.5M more in revenue than Q4 2024, GAAP net income fell by $27M. This reversal was fueled by a 50% YoY increase in Total Operating Expenses ($136.7M vs $91.1M). Specifically, G&A expenses skyrocketed 99% to $57.6M, and R&D jumped 44% to $49.9M. While pipeline investments justify some R&D growth, the massive G&A spike contradicts the narrative of scaling a highly profitable, self-funding commercial engine.
WAKIX Patient Funnel Remains Remarkably Stable
Commercial execution is highly consistent. Average patients on WAKIX grew by ~400 for the third consecutive quarter, reaching ~8,500 in Q4. Recent FDA approval for pediatric cataplexy (February 2026) provides an immediate incremental growth driver, allowing full promotional efforts to tap into a previously restricted patient pool.
Pitolisant Lifecycle Extension Strategy
To counter the 2030 generic cliff, Harmony is accelerating its next-generation formulations, designed to push exclusivity into the 2040s. The 'fast-to-market' Pitolisant GR (gastro-resistant) eliminates the need for titration and expects an NDA submission in Q2 2026. Simultaneously, Phase 3 trials for Pitolisant HD (high-dose) targeting fatigue and sleep inertia initiated in Q4 2025, offering enhanced efficacy and differentiated indications.
ANDA Litigation and Generic Cliff
Harmony completed settlements with 3 additional generic filers, bringing the total to six of the seven ANDA filers. The settling parties will receive licenses to launch no earlier than March 2030 (assuming pediatric exclusivity is granted). While this provides a clear runway for the next four years, the impending LOE requires flawless execution on the pipeline to replace WAKIX revenues post-2030.
Orexin-2 Agonist (BP1.15205) Advancing as Best-in-Class Contender
Harmony is pursuing technology innovation in the highly competitive orexin space. Phase 1 clinical studies for BP1.15205 are ongoing, with PK data anticipated in mid-2026. Management notes this molecule utilizes a novel chemical scaffold offering high preclinical potency, selectivity, and the potential for true once-a-day dosing—critical differentiators against advancing rival orexin programs.
ZYN002 Program Officially Phased Out
Following the Q3 2025 failure of the Phase 3 RECONNECT study in Fragile X syndrome, Harmony has officially removed ZYN002 from its forward-looking catalyst milestones. The company is no longer pursuing the 22q deletion syndrome indication. This concentrates risk heavily onto the remaining sleep/wake (Pitolisant/Orexin) and epilepsy (EPX-100) programs.
Supply Chain De-Risking Amid Macro Pressures
As noted in prior quarters, management has actively mitigated geopolitical and macro supply chain risks by establishing secondary U.S.-based manufacturing for WAKIX and ensuring U.S.-domiciled IP and manufacturing for Pitolisant HD, insulating the company's core assets from international trade disruptions.
Other KPIs
Accelerating. Up from $576.1M at the end of 2024. Despite the Q4 earnings compression, the company remains a robust cash generator, fully capable of self-funding its extensive Phase 3 pipeline and pursuing opportunistic, value-enhancing business development without tapping capital markets.
Accelerating. Up 30% YoY from $145.8M. Reflects the cost of advancing multiple late-stage programs simultaneously, including $19.25M in combined IPR&D milestone charges across BP1.15205, ZYN002, and the CiRC collaboration throughout the year.
Guidance
Decelerating slightly in percentage terms but remaining highly robust. The midpoint of $1.02B implies ~17.5% YoY growth, compared to the 22% growth achieved in FY25. Hitting this target will officially elevate WAKIX to blockbuster status in the narcolepsy space.
Key Questions
Drivers Behind Q4 G&A Surge
G&A expenses nearly doubled year-over-year in Q4 to $57.6M. How much of this is related to one-time legal or settlement costs versus permanent structural run-rate increases to support commercial expansion?
Remaining ANDA Filer
With settlements reached with six of the seven generic filers, what is the litigation status and assumed risk profile regarding the single remaining holdout?
MS Fatigue Clinical Strategy
As you explore broader CNS indications like MS fatigue for the new pitolisant formulation, what specific clinical endpoints will you target to differentiate from traditional stimulants, and what is the expected timeline to enter the clinic?
M&A Capital Deployment
With nearly $900M in cash and the ZYN002 program phased out, is management looking to accelerate business development to fill the void in the neurobehavioral franchise, or will capital deployment focus strictly on sleep/wake and epilepsy?